Drug Trial Radar · NCT07930572
A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria (CSU)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Mar 31, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Novelty Nobility, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
NN2802 is a new product that is being developed for treating participants with CSU who remain symptomatic despite treatment with antihistamines. NN2802 is not yet an approved product and it can only be used in an experimental study like this one. The purpose of this study is to learn more about a new experimental drug called NN2802. NN2802 is an investigational fully human monoclonal antibody that inhibits c-Kit. c-Kit is involved in the survival, development, and activity of mast cells, which are important cells involved in allergic and inflammatory reactions. By inhibiting c-Kit, NN2802 may reduce mast cell numbers and activity and may help improve symptoms of CSU, such as hives, itching, and angioedema. The study will assess the safety, tolerability, pharmacokinetics (PK, amount of drug in your blood), pharmacodynamics (PD, how the drug affects your body), immunogenicity (whether your body develops antibodies against the study drug), and preliminary efficacy (whether the drug may improve CSU symptoms) of NN2802. It also aims to identify suitable doses and dosing schedules of NN2802 for use in future clinical trials. This study will be conducted at multiple study sites, involving around 44 to 46 participants in total, including healthy participants and participants with CSU who remain symptomatic despite treatment with antihistamines. The number of participants depends on how well the study participants tolerate the treatment and the number of dose groups studied.
Conditions
- Healhty
- Chronic Spontaneous Urticaria (CSU)
Interventions
NN2802Drug
Investigational product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence of Adverse EventsTime frame: 14 weeks
- Part B: Incidence of Adverse EventsTime frame: 22 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hangzhou First People's Hospital
Hangzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.